Evidence map›Paper›PMID 41671528›Full record

ArticleJCO global oncology2026

Prospective Cohort Study Testing Interventions to Reduce Diagnosis Delay and Treatment Abandonment of Children With Burkitt Lymphoma in Kenya.

Sandra Langat, Festus Njuguna, Nicholas Kigen, Martha Kipngetich, Gilbert Olbara, Ann Moormann, Gail H Vance, Teresa Lotodo, Boaz Odwar, Patrick J Loehrer and 3 more

Abstract read
In one paragraph

Article in JCO global oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sandra LangatAcademic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya.ORCID 0000-0001-8867-5616
Festus NjugunaMoi University, School of Medicine, Eldoret, Kenya.
Nicholas KigenEmma Children's Hospital, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands.
Martha KipngetichEmma Children's Hospital, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands.
Gilbert OlbaraMoi Teaching and Referral Hospital, Eldoret, Kenya.ORCID 0000-0002-7795-8474
Ann MoormannUniversity of Massachusetts Chan Medical School, Worcester, MA.
Gail H VanceDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN.ORCID 0000-0002-7424-2921
Teresa LotodoMoi University, School of Medicine, Eldoret, Kenya.
Boaz OdwarKenya Medical Research Institute, Kisumu, Kenya.ORCID 0000-0001-8252-1333
Patrick J LoehrerIndiana University, School of Medicine, Indianapolis, IN.ORCID 0000-0002-1532-4660
Gertjan KaspersEmma Children's Hospital, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands.ORCID 0000-0001-7716-8475
Saskia MostertUnaffiliated Researcher, Heeerhugowaard, the Netherlands.ORCID 0000-0002-4583-8603
Terry A VikMoi University, School of Medicine, Eldoret, Kenya.

Funding

Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI Sara K Quinney · 1999 to 2026
$59.3M
NCI NIH HHS P30 CA082709
6 · The paper itself

Abstract

purposeLow survival rates among children with Burkitt lymphoma (BL) in low- and middle-income countries (LMICs) are caused by multiple factors, including delays in diagnosis and treatment abandonment. These issues are often linked to the cost of diagnostic tests, treatment, and transportation. This study describes the implementation and effectiveness of a program targeting these issues among children with BL in Kenya.

methodsChildren with symptoms suggestive of BL between 2017 and 2018 were prospectively enrolled in an intervention program including (1) Diagnosis Delay Intervention by performing flow cytometry and covering its cost and (2) Treatment Abandonment Intervention by reimbursing transportation costs, compensating for some lost family income because of the child's hospital stay, and sending reminder phone calls. A medical record review was conducted to perform a historical comparison of diagnosis delay and treatment outcomes between two cohorts (2010-2016

resultsForty-three patients who had a pathologically confirmed diagnosis of BL were enrolled in the intervention program. When comparing the historical cohort (2010-2016; N = 138) and the prospective cohort (2017-2018; N = 43), it was found that after implementing the program, the mean time to diagnosis decreased from 13.57 days to 10.58 days (

conclusionThe combination of timely diagnosis and modest financial support for families to complete treatment significantly improved the survival rate of children with BL in our study. This program has the potential to be implemented for children with other cancers and in other LMIC settings.

Indexed as

Burkitt LymphomaDelayed DiagnosisChildChild, PreschoolFemaleHumansInfantKenyaMaleProspective StudiesTreatment Delay

Identifiers

PMID41671528
PMCPMC12900048

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.